Agoracom Blog Home

Posts Tagged ‘investments’

« Older Entries
Newer Entries »

Datametrex $DM.ca Strengthens Board With Appointment of Benj Gallander

Posted by AGORACOM-JC at 2:30 PM on Thursday, June 25th, 2020
  • Announced the appointment of Mr. Benj Gallander as a new independent member of the Board of Directors
  • Benj has worked with start-ups and corporations of various sizes.
  • He has built his company over 25 years and understands the buy side in great detail, as well as corporate turnarounds
  • His background in investments greatly strengthens our company,” stated Marshall Gunter, CEO of Datametrex. “Benj is highly accomplished and connected within the investor community.”

TORONTO, June 25, 2020 – Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce the appointment of Mr. Benj Gallander as a new independent member of the Board of Directors.

“Benj has worked with start-ups and corporations of various sizes. He has built his company over 25 years and understands the buy side in great detail, as well as corporate turnarounds. His background in investments greatly strengthens our company,” stated Marshall Gunter, CEO of Datametrex. “Benj is highly accomplished and connected within the investor community.”

To support Datametrex’s growth, Mr. Gallander brings over 40 years of experience in the markets, with ample skills in integrating business and strategic investors and his know-how bringing innovation to companies.  Over time, he has refined his approach to investing and has achieved one of the best track records in the investment industry. Mr. Gallander is co-editor of Contra the Heard investment letter and over the past ten years the portfolio he manages achieved an annualized return of 18.4%. Benj co-writes “The Contra Guys” column for The Globe and Mail and is an author of three best-selling books, writes for several magazines, and has been a regular on BNN Bloomberg since virtually the beginning.

“Datametrex is poised to leverage their technology acumen and proven client solution capability. Datametrex’s recent initiative in COVID-19 testing kits has enabled the company to transform and breakthrough into society as a trusted and essential partner. I am looking forward to working with Marshall and the team at Datametrex,” said Benj. 

The company has issued Mr. Gallander 1,000,000 options at a strike price of C$0.10, being the closing price of the common shares of the Company on June 24, 2020.

As part of Board changes, Charles Schade is stepping down from the Board and will be joining the Company’s Advisory Board. Charles joined the company from the start and was the longest serving Board member.  The Company would like to thank Charles for his active contribution to the Board and looks forward to continuing to work with him as a member of the Advisory Board to the Company.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , ,
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Strengthens Board With Appointment of Benj Gallander

Datametrex $DM.ca Completes Shipping of Second $500,000 Purchase Order to Canadian Mining Company

Posted by AGORACOM-JC at 7:23 AM on Wednesday, June 24th, 2020
  • Company has completed shipping the second 10,000 purchase order of COVID-19 test kits to a Canadian based mining company with operations worldwide
  • Total gross sales amount is approximately $500,000 CDN, excluding shipping fees
  • Datametrex anticipates that it has little or no upfront costs associated with the sale of these test kits

TORONTO, June 24, 2020 — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that the Company has completed shipping the second 10,000 purchase order of COVID-19 test kits (the “PO”) to a Canadian based mining company with operations worldwide.

The total gross sales amount is approximately $500,000 CDN, excluding shipping fees. Datametrex anticipates that it has little or no upfront costs associated with the sale of these test kits.  All of the items are shipped from manufacturers to the purchaser’s mine operating sites in Ontario and Quebec.

Under the terms of the PO, Datametrex provides them with an initial 10,000 units of the COVID-19 qPCR Detection Kits manufactured by 1drop Inc. (“1drop”), 10,000 Universal Transport Medium (UTM®), Sterile Swabs with 16x100mm and Skirted Tubes. The Company also shipped two (2) Real-Time Polymerase Chain Reaction Detection System (“PCR”) machines along with software to ensure optimal assay performance of the samples.

“I think our industry has taken COVID-19 extremely seriously,” said Pierre Gratton, President and Chief Executive officer of the Mining Association of Canada to the Financial Post. “By implementing testing in their operations and conducting contact tracing of the infected individuals, this Mining conglomerate is closely monitoring the safety of its workers and surrounding communities to continue to operate responsibly and efficiently.”

“Datametrex is proud of being at the forefront of COVID-19 testing technologies and is pleased to facilitate solutions to help contain the spread and a potential resurgence of the virus,” says Marshall Gunter, CEO of the Company. “We want to help companies in the process of curtailing the second wave threatening society and the global economy.”

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , ,
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Completes Shipping of Second $500,000 Purchase Order to Canadian Mining Company

Datametrex $DM.ca Sold $1.5m Test Kits and Provides 90 Day Corporate Update on #COVID19 With Sales Outlook

Posted by AGORACOM-JC at 8:01 AM on Thursday, June 18th, 2020
  • Company has sold approximately 30,000 test kits and 7 PCR (Polymerase Chain Reaction) machines to several Canadian companies
  • Total gross sales of approximately $1.5 million CAD
  • Datametrex has little or no upfront costs associated with the sale of these test kits
  • Company’s project pipeline is significant on both the COVID-19 test kits and Personal Protective Equipment based on multiple projects in various stages of development across Canada, US, Africa, Asia, Australia and the EU

TORONTO, June 18, 2020 – Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to share a corporate update that since announcing on April 16, 2020, that it secured the rights to import and sell high-quality South Korean manufactured Nucleic Acid COVID-19 test kits.

Datametrex continues supporting companies through facilitating COVID-19 test kits, along with big data AI analytics tools that can help target future outbreaks, potentially source fake news that can be detrimental to the operations, or even visualize the audience that needs the fastest response in these critical times.

NEW REVENUE

The Company has sold approximately 30,000 test kits and 7 PCR (Polymerase Chain Reaction) machines to several Canadian companies, for total gross sales of approximately $1.5 million CAD. Datametrex has little or no upfront costs associated with the sale of these test kits.

HIGHLIGHTS

  • Since May 15th, Datametrex has generated gross sales of $500,000 with the sale of 10,000 test kits and one (1) PCR machine to a large Canadian mining company with operations in West Africa.
     
  • Since June 8th, Datametrex has sold $810,000 with initial orders comprising of 12,000 test kits and six (6) PCR machines to two Canadian companies.

  • On June 9th the Company arranged with lab partner Transpharm Canada Inc. (“TCI”) to conduct ongoing testing for a private Quebec metal mining company with an initial order of 2,000 test kits generating gross sale of approximately $250,000 for Datametrex.

“With the resurgence of a second wave of COVID-19 in multiple countries, and with a worldwide attempt to reduce lockdown measures to get citizens back to work, the demand for testing will only increase. These rapid antibody-based tests are a vital tool for jumpstarting the economy,” says Marshall Gunter, CEO of the Company. “Datametrex is pleased to facilitate the sale of these test kits globally providing worldwide, the opportunity to use top quality test kits to flatten the curve and get back to the “new normal” safely.”

Advisory Board and New Personnel

On May 4th, Todd Shapiro consented to join the Board of Directors of Datametrex. After being a top rated Radio Show host & a brilliant marketing Entrepreneur with over 20 years of experience, he has recently moved on from main stream media to concentrate his efforts on being the CEO of Red Light Holland. Todd currently sits on the Board of Directors for Red Light Holland, JamStacked and Mogul Productions.

On May 19th, Datametrex added President and Dean of the Toronto Institute of Pharmaceutical Technology (“TIPT”) and Clinical Pharmacologist, Dr. Alexander MacGregor, Ph.D., to the Company’s Medical Advisory Board.

On June 10th, the Company welcomed Edward Choi, to head up the sales team in Seoul, South Korea. Edward was a Vice President at LOTTE for leading Lotte’s cyber security division.

Datametrex Pipeline

The Company’s project pipeline is significant on both the COVID-19 test kits and Personal Protective Equipment (“PPE”) based on multiple projects in various stages of development across Canada, US, Africa, Asia, Australia and the EU. We are waiting for PO approvals with specified COVID-19 sales and or tender proposal process. The Company will recognize revenue upon sale and shipment of the test kits. The Company will also receive additional revenue streams as we secure new business and continue to provide Ai services, fullfill contracts and or supply agreements to goverments, corporate customers upon fulfillment.

About Transpharm Canada Inc.

Transpharm Canada Inc. provides pharmaceutical education, technology, and research opportunities to students through its subsidiary, Toronto Institute of Pharmaceutical Technology, North America’s premier pharmaceutical training institute. The facility is also fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies. Additional information on TIPT is available at www.tipt.com

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , ,
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Sold $1.5m Test Kits and Provides 90 Day Corporate Update on #COVID19 With Sales Outlook

Datametrex $DM.ca Obtains Rights to Sell COVID-19 Home Test Kits With FDA Registration

Posted by AGORACOM-JC at 8:11 AM on Tuesday, June 16th, 2020

– Secured non-exclusive rights to sell RapiGEN Inc. (“RapiGEN”) COVID-19 home test kitsi.

– These test kits are FDA registered, suitable for point of care testing, no extra equipment is needed, and are easy to use with results in 5-10 minutes.

TORONTO, June 16, 2020 – Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured non-exclusive rights to sell RapiGEN Inc. (“RapiGEN”) COVID-19 home test kitsi. These test kits are FDA registered, suitable for point of care testing, no extra equipment is needed, and are easy to use with results in 5-10 minutes.

If the specimen contains IgM antibodies to SARS-CoV-2, a colored line appears in the T line area. The RapiGen home test kit is a lateral flow immunochromatographic assay (LFIA) for the qualitative detection of IgG antibodies to COVID19 in blood, serum or plasma specimens.

Watch the sample video of the test here: https://datametrex.com/investor/video.html

The Company’s primary goal is to sell to the current clients for their operations out of Canada, and the Company intends to apply for Health Canada approval with an Interim Order (“IO”).

“These test kits are revolutionary in expediting the process of testing since it cuts out the processing time by a fraction, aiding in an earlier detection of the virus, a more accurate prediction of the positive cases and a decrease of the infection rate,” said Marshall, CEO of the Company.

“Having seen the urgent need for COVID-19 test kits, Datametrex is doing everything it can to help Canada combat COVID-19 and flatten the curve. In the meantime, having FDA registration under EUA allowing us to help our neighbours to the south and any Canadian company with operations in the US and Europe,” says Andrew Ryu, Chairman of the Company.

The Company’s ability to fulfill any purchase order for Covid-19 test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits.

The Company is exploring oportunities with Michigan Economic Development Corporation and Governor’s Office of Business and Economic Development in California looking into retail, film, healthcare oportunities. With months into the spread of the COVID-19 in Califoria, widespread diagnostic testing still isn’t available. Testing voids, stemming from an overwhelmed supply chain and a disjointed public health system, have hit hardest in California’s rural north. The Michigan Department of Health and Human Services, Michigan State Police, and local health departments are looking to expand COVID-19 testing directly to the community. Michegan now is easing coronavirus restrictions with six-part reopening plan that includes testing to ensure the state lowers the chance of a second wave and to further protect Michigan families.

About RapiGEN Inc.
RapiGEN has the manufacturing technology of Gold colloid which is the core material of immunochromatographic assay. RapiGen has developed a convenient, quick and accurate diagnostic kit, focused on developing distinctive next-generation diagnostic kits from existing products. Currently researching and developing various diagnostic kits for increasingly epidemic pathogenesis such as Covid-19, Shigella, Cholera and Entrohemorrhagic E.coli. Additional information on RapiGEN is available at http://rapigen-inc.com/

About Food and Drug Aministration EUA
On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.

About Datametrex
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

i Source: FDA [RAPIGEN INC] – BIOCREDIT COVID-19 IgG+IgM Duo -https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=680769&lpcd=QKO    

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5d8342b8-7212-4584-8839-edd666c79914

RapiGEN COVID-19 Home Test
RapiGEN COVID-19 home test kit procedure instructions.

Tags: , , , , , , ,
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Obtains Rights to Sell COVID-19 Home Test Kits With FDA Registration

Datametrex $DM.ca Received the Final Payment on Completed Shipping of COVID-19 Test Kit Order

Posted by AGORACOM-JC at 8:38 AM on Friday, June 12th, 2020
  • Company has received the full and final payment from its purchaser and completed shipping the first purchase order of COVID-19 test kits for a mining company employees in multiple jurisdictions outside of Canada, as announced on May 15th 2020
  • The total gross sales amount is approximately $500,000 CDN, excluding shipping

TORONTO, June 12, 2020 — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that the Company has received the full and final payment from its purchaser and completed shipping the first purchase order (the “PO”) of COVID-19 test kits for a mining company employees in multiple jurisdictions outside of Canada, as announced on May 15th 2020.

The total gross sales amount is approximately $500,000 CDN, excluding shipping.

Under the terms of the PO, Datametrex sold to the purchaser an initial 10,000 units of the iONEBIO Inc. iLAMP Novel-CoV19 Detection Kit; 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples. The iONEBIO test kits provide results within approximately 15 to 20 minutes.

All of the items are shipped directly from manufacturers to the purchaser’s mine operating sites. Security clearance backlogs continue to streamline as Governments align with the World Health Organization’s remarks on the importance of testing. Governments have urged mining companies to implement testing and screening their workforce to properly fight the virus in order to avoid further closures.

“The opportunity to use an advanced COVID-19 testing kits from our partners from Korea to support the diagnostic potential for populations provides an exciting opportunity for countries during this pandemic and the African continent,” says Marshall Gunter, CEO of the Company. “Datametrex is honored to be assisting in the health and welware of mine employees and local contractors.”

According to Africa Centres for Disease Control and Prevention (the “Africa CDC”), there are over 150,000 cases of COVID-19 throughout Africa and with this, Researchers at the African Center of Excellence for Genomics of Infectious Diseases (the “ACEGID”) and other research and public health partners, have announced to implement a Sentinel Project (the “Sentinal”) surveillance protocol for an early warning system in Africa. The Sentinel is the first of eight new projects selected, and it has three pillars are: (1) detect, (2) connect and (3) empower. And in the third pillar, the project will empower public health experts by training thousands of healthcare professionals to use the sentinel tools and deploy the diagnostic technologies for population-level COVID-19 testing, building on previous experiences of ACEGID and the Broad Institute in training over 900 individuals from around the world.

Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , ,
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca Received the Final Payment on Completed Shipping of COVID-19 Test Kit Order

VIDEO: Datametrex $DM.ca #COVID19 Test Kit Sales Of Approx $1.5M & 26,000 Units – Are Just PILOT PROJECTS

Posted by AGORACOM-JC at 6:43 PM on Thursday, June 11th, 2020

On April 16, Datametrex AI  announced it had obtained the rights to import and sell COVID-19 test kits from South Korea, due to a request for help from the Canadian Government who needed a partner with high-level security clearances.

On May 15, Datametrex AI reported its first sale of $500,000 for 10,000 units to a Canadian mining company.

By today’s interview (June 11) Datametrex has announced approximately $1,500,000 in sales, representing approximately 25,000 COVID-19 test kits.
Any company and their investors would be very happy with these results give the fact it’s Q3 sales (March 31 and Pre-COVID) were $810,000 strictly from Artificial Intelligence.

But CEO Marshall Gunter then dropped a bomb on us …. the ~25,000 Units and $1.5M in COVID-19 test kit sales are PILOT PROJECTS, the definition of which according to QUORA is:

” A pilot project is an initial smaller scale implementation of a larger project that is used to work out issues and roadblocks prior to going all out with the full project.“

Clearly, Datametrex has something potentially bigger in mind, assuming all goes well with these pilot projects.  How well are they going?  Who else are they talking to?  How far could the “full project” go?

The answers to those questions will come from our latest interview with Datametrex AI CEO, Marshall Gunter.  

Datametrex AI (DM: TSXV) is a great Canadian small cap technology company, who is giving small cap investors an opportunity to participate in the emerging world of Artificial Intelligence, as well as, the brand new world of COVID-19 testing.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , ,
Posted in AGORACOM Via Satellite, Datametrex AI Limited, Featured | Comments Off on VIDEO: Datametrex $DM.ca #COVID19 Test Kit Sales Of Approx $1.5M & 26,000 Units – Are Just PILOT PROJECTS

Could #COVID19 be telehealth’s big moment? #Mhealth – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:27 AM on Thursday, May 14th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Could COVID-19 be telehealth’s big moment?

  • Over the five-year period that the analysis looks at, the U.S. telehealth market could see a compound annual growth rate (CAGR) of 38.2%
  • This year alone, the analysts expect the market to experience year-over-year growth of 64.3%

By Sean Whooley

Frost & Sullivan announced today that recent analysis finds that the demand for telehealth technology is expected to rise amid the COVID-19 pandemic.

The analysis, titled “Telehealth — A Technology-Based Weapon in the War Against the Coronavirus, 2020,” revealed that, as COVID-19 continues to disrupt the practice of medicine and the delivery of healthcare, the U.S. telehealth market will experience seven-fold growth by 2025.

Over the five-year period that the analysis looks at, the U.S. telehealth market could see a compound annual growth rate (CAGR) of 38.2%. This year alone, the analysts expect the market to experience year-over-year growth of 64.3%.

“The critical need for social distancing among physicians and patients will drive unprecedented demand for telehealth, which involves the use of communication systems and networks to enable either a synchronous or asynchronous session between the patient and provider,” Frost & Sullivan healthcare principal analyst Victor Camlek said in a news release. “However, all stakeholders need to remember that many people use the terms ‘telehealth’ or ‘telemedicine’ without understanding the ecosystem that is involved. This study will clarify the many components that are needed in order to implement telehealth.”

Camlek said that virtual visits and remote patient monitoring will propel the telehealth market, then mHealth and personal emergency response systems will come into play as well.

The analysis hypothesizes that the opportunity for telehealth to become the standard of care is growing amid the pandemic and the main challenge for providers is the capabilities for scaling up during the increase in demand.

Frost & Sullivan expects growth to be sustained beyond the pandemic by vendors who deliver user-friendly sensors, practical applications of artificial intelligence, interactive virtual assistants and robotics, as well as use of big data analytics and adherence to cybersecurity, among other things.

Source: https://www.medicaldesignandoutsourcing.com/could-covid-19-be-telehealths-big-moment/

Tags: , , , , , , ,
Posted in All Recent Posts, CardioComm Solutions | Comments Off on Could #COVID19 be telehealth’s big moment? #Mhealth – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

How is #COVID19 Impacting the #Mhealth Sector? – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 9:00 PM on Monday, May 11th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

How is COVID-19 Impacting the mHealth Sector?

 

– COVID-19 is set to challenge the traditional working of the healthcare domain and push it towards an expedited adoption of digital health.

– The one thing that is certain amidst this time after the pandemic impact has ended, we all will be left with structural changes in ways healthcare works.

By Prateek Saxena

As you read, COVID-19 is shutting down one nation after another. Around the globe, the coronavirus pandemic is having an unprecedented effect on daily lives. The virus has contacted every single sector as part of its dire impact on the global economy.

But its impact on the healthcare sector has been seismic. 

COVID-19 is set to challenge the traditional working of the healthcare domain and push it towards an expedited adoption of digital health. 

The value of digital approaches which are designed to help health professionals and the public stay up to date about the disease, maintain communication, and allow better strategic planning are now being highlighted more than ever before. 

The one thing that is certain amidst this time after the pandemic impact has ended, we all will be left with structural changes in ways healthcare works. Although these changes were happening, they were piecemeal. COVID-19 is everything that is needed to expedite the process and bring upon the digital transformation. 

Here’s a detailed read on the coronavirus impact on healthcare industry. 

How is mHealth changing?

Medical Distancing: To counter COVID-19 outbreak, key authorities like the WHO and CDC have been lobbying for ways to lower physical contact between the healthcare providers and patients, also known as medical distancing. 

Telehealth service is becoming a force in the efforts to lower healthcare-specific COVID-19 transmission. It’s effectiveness has been acting as a promising one for areas including dermatology, cardiology, and diabetic care, etc. which allows high-quality remote care, all the while saving the time and physical space. 

Even though telehealth has established itself as a great measure to back up medical distancing, there are certain barriers that have to be addressed. There are issues around patient characteristics like educational background and age, etc, uncertainties around the legal liabilities, in addition to issues of confidentiality and privacy. 

Healthcare app development companies, however, have taken notes and are working on eradicating these issues. 

Crowdsourced disease monitoring: the high surge of coronavirus crisis are highlighting the need of timely tracking the infected and their contacts. Flexibility and timeliness are known to be the two common weaknesses in the surveillance systems.  

Digital health experts, through the mode of coronavirus tracing applications, make it possible to crowdsource disease monitoring. People from across the world put in their data – their travel routes, prospect of them having caught the virus, etc. for the healthcare agencies to track the hotspots and carriers. 

Health Information Exchange to boost interoperability: Because of the pandemic and the overcrowding of patients and health facilities, a strong health data exchange has become a key in the health infrastructure. It has also shown us that ‘health data’ shouldn’t just consist of patients’ medical data but also consist of a wide data type coming in from individual’s offline and online activity. 

We are going to see a lot more HIEs becoming open and un-localized. There will be many portals coming into existence for the patients and health systems to access the files. 

“With the coronavirus exploding in communities and overwhelming hospitals nationwide, we need to help doctors and nurses on the front lines get the information they need now to stop the spread of this virus and save lives,’’ Allen Byington, co-founder of HIE Networks said. “There has never been a greater need for easy, seamless communications in health care.”

Surging demand for health gadgets: The coronavirus impact on healthcare sector has been a seismic wave of wellbeing awareness and anxiety. The fear of infection has expedited the adoption of applications and wearable as a mode of making people feel protected. Wearables are giving people accurate feedback on their blood pressure, body temperature, and health signals which are restoring the sense of control in people in addition to helping them track their health. 

In addition to the rising demand and usage of wearable for preventive measures, the users are also adopting them for being fit and keeping up with their fitness goals that they have set for themselves. 

Companies using technology to track, test, and treat COVID-19

  1. Apple & Google announced their plan to launch APIs which would enable interoperability between Android and iOS products. The two companies are also committed to developing bluetooth-based contact training features in their underlying operating systems. They believe that it would provide deeper data integration with the governments’ public health initiatives and health apps. 
  2. Walgreens has expanded its telehealth program in a way that it includes COVID-19 risk assessment, information on the clinical trials, etc. The platform also includes a website and mobile health application to help patients navigate telehealth providers and health systems so that they can connect with nurses and doctors. 
  3. The Kingdom of Bahrain has developed a COVID-19 tracking system which depends on the GPS tracking electronic bracelets and coronavirus contact tracing application. The system then alerts the government monitoring station when the infected individual leaves isolation. 
  4. Acute care and SCP Health declared their partnership for providing scalable emergency service and hospital medicine through telemedicine 
  5. Jefferson Health system laid a partnership with LifeLink for launching former’s chatbot across LifeLink’s 14 Philadelphia locations. The chabot would make use of AI for aiding pre-screen of coronavirus outbreak. The patients can also make use of the bot for figuring out the right approach of their treatment. 

In conclusion: The post-coronavirus digital health

The after-COVID world is going to be remembered as when medical interactions such as a provision to primary care or management of several non-communicable diseases transferred to digital mode, by default, as opposed to exceptions. While we had very little impact on how coronavirus impacts the global digital health industry, the post-COVID19 world will see us accepting digital health as the new normal. 

The new age will also likely enable other technologies like 5G, AI, IoT, etc. to help us all converge in a completely new variety of approaches. In this global pandemic, we are witnessing this happening in real-time and in a never-imaginable pace. 

In England, primary care has now started finally embracing telehealth and has been delivering a digital first approach as a mode to manage streaming care to the appropriate places. 

However, there’s plenty left to be done. There is a need for incorporation of a robust governance in deployment of these approaches. There should also be a robust clinic decision support within our deployments as a rule in place of exceptions. 

The next important alteration which can be seen accelerating is an adoption of precision health: both in personalised and predictive health setup. We will see the utilization of digital technology in empowering the people to self-manage themselves in case of non-communicable disease. 

Additionally, we have to understand that this new world of medical infrastructure will be very different from the health and care world we are used to. It would require us to remain open and adaptive. There is one thing guaranteed – the digital health world is going to change for the good.

Source: https://appinventiv.com/blog/coronavirus-impact-on-mhealth/

Tags: , , , , , , ,
Posted in All Recent Posts, CardioComm Solutions | Comments Off on How is #COVID19 Impacting the #Mhealth Sector? – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

#Mhealth Study to Test Cardiac Effects of Potential COVID-19 Treatment – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 9:35 AM on Friday, April 24th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

mHealth Study to Test Cardiac Effects of Potential COVID-19 Treatment

A French study will use a smartwatch and mHealth platform to monitor ECG data from COVID-19 patients being treated with hydroxychloroquine, a potential therapy for the Coronavirus but one that may have serious side effects.

  • An mHealth study being launched in France will use an mHealth wearable to monitor cardiac activity in COVID-19 patients being treated with hydroxychloroquine and azithromycin, a drug therapy eyes as a potential treatment for the Coronavirus.

Source: ThinkStock

By Eric Wicklund

April 22, 2020 – An mHealth study being launched in France will use an mHealth wearable to monitor cardiac activity in COVID-19 patients being treated with hydroxychloroquine and azithromycin, a drug therapy eyes as a potential treatment for the Coronavirus.

Researchers at the University Hospital of Marseille will be using a smartwatch develop by Withings and integrated with an AI-based mHealth platform developed by Boston-and-Paris-based Cardiologs. The platform is designed to remotely monitor a user’s ECG data for QT prolongation.

“A significant QT prolongation can lead to ventricular arrhythmia and potentially deadly consequences” Laurent Fiorina, a cardiologist at the Institut Cardiovasculaire Paris Sud (ICPS) and Cardiologs executive who helped launch the study, said in a press release. “It is thus important to closely monitor the QT interval during this treatment.”

“The objective of our study is to evaluate a new method for QT measurement using Cardiologs’ AI-based solution and ECG data collected via smartwatches,” added Professor Jean-Claude Deharo, head of the cardiac arrhythmia department at the University Hospital of Marseille and the principal investigator of the study. “Smartwatches are already used in the clinical setting but do not have validated QT analysis available. Combining these technologies will enable clinicians to overcome the practical limitations in the context of COVID-19 of the standard cardiac safety strategy that requires heavy patient interaction.”

Often used to prevent or treat malaria caused by mosquito bites, hydroxychloroquine has be held up by several people – including President Donald Trump – as a potential means of treating the Coronavirus. But many in the healthcare industry have pointed out the drug’s potentially dangerous side effect.

Researchers are hoping to determine whether the treatment does pose a threat to a patient’s health – and whether this platform can be used in other non-COVID-19 treatments.

“This study has implications for risk management of drug-induced cardiotoxicity, even beyond the current COVID-19 and hydroxychloroquine context,” Professor Jag Singh, a cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and scientific advisor to Cardiologs, said in the press release. “Personal ECG sensors could potentially find a role in the management of these patients, but also add value in other routine clinical care, since over 300 commonly used drugs may have similar QT-prolongation risks as hydroxychloroquine.”

Source: https://mhealthintelligence.com/news/mhealth-study-to-test-cardiac-effects-of-potential-covid-19-treatment

Tags: , , , , ,
Posted in All Recent Posts, CardioComm Solutions | Comments Off on #Mhealth Study to Test Cardiac Effects of Potential COVID-19 Treatment – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Using #Telehealth in a #Pandemic #Covid19: Focus on Flexibility, Scalability – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 9:40 AM on Monday, April 6th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Using Telehealth in a Pandemic: Focus on Flexibility, Scalability

Executives from three different health systems talk about how they’ve used telehealth to meet the demands created by the Coronavirus pandemic – and how those services are laying the groundwork for ‘the new normal.’

By Eric Wicklund

  • Healthcare providers are scrambling to keep up with the demand for telehealth services as the Coronavirus pandemic sweeps across the nation
  • Many are seeing unexpected benefits in the shift to connected health – and hoping the momentum continues after the emergency is over

‘Take Care of the Patients First’

“There’s been a lot of spontaneous action,” says Alexa Boer Kimball, CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, a network of roughly 2,900 physicians spread across eastern Massachusetts.

“The key is to take care of the patients first,” she says.

Kimball remembers using telemedicine as far back as 1998, though more recently the network had focused on urgent on-demand care. Now her physicians are seeing thousands more patients each week via telehealth than they had seen just a few weeks ago.

While the traditional barriers – reimbursement, patient and provider buy-in, technology – “have always been there,” Kimball says the accelerated pace of the nation’s response to the emergency has allowed providers to jump in and try things out.

“The first thing we realized was that you can do a lot of things just on the phone,” she says.

Actions by state and federal officials have loosened a lot of those barriers, allowing providers to test new platforms and see more reimbursement. Kimball says her providers have long clashed with payers over coverage, and she’s hoping the success they’re seeing now will convince payers to maintain these new guidelines after the pandemic has eased.

“Right now we’re pretty confident we’ll be reimbursed for that business, but we’re still not sure,” she says. “This (rapid uptake) is kind of proof in the pudding. We need to make sure we have the data to prove our point.”

Kimball advises providers to “pay attention to all the guidance” right now, identifying both state and federal guidelines that have a direct effect and positioning telehealth and mHealth services to take advantage of those new rules. This includes developing a compliance and payer-specific billing plan, and massaging that plan to cover not just Coronavirus cases, but all cases.

“We need to be ready for a new (environment),” she says. “There’s no going back.”

‘We … Jumped Forward 10 Years on the Adoption Curve’

Out in Renton, WA, the Providence St. Joseph Health system was caught in the middle of the first wave of Coronavirus cases. But Aaron Martin, Executive Vice President and Chief Digital Officer for the six-state, 51-hospital health system, says leadership had recognized the value of virtual care six years ago and had the infrastructure in place to tackle the surge.

Still, he says, they were caught by surprise by a tenfold increase in telehealth visits and a sevenfold jump in care providers joining the platform.

“We had to move very quickly from feature-driven (virtual health offerings) to scale-driven,” he says. “We basically jumped forward 10 years on the adoption curve.”

Martin says PSJ has a large digital health innovation program, employing some 120 software engineers and producing more than a few tools and incubator spin-outs, like Xealth. The health system also partners with telehealth and mHealth companies to test out the latest in tools and services.

That helped the health system expand from its fast-growing ExpressCare Virtual telehealth platform to a stable of services that now includes remote patient monitoring for roughly 300 patients in the Seattle area. That program will soon be expanded throughout the enterprise to help other hospitals manage their populations at home. 

Martin says the health system realized very quickly that it had to have a plan in place for expanding and evolving its virtual care services. 

“Move fast, but make sure you’re being very, very diligent about things,” he says. “Understand all the processes in place, and make sure the technology is very fungible and easy to configure.” 

In addition, make sure all telehealth and mHealth services are tested and fine-tuned not only by IT, but by the clinicians who will use them. 

“And be prepared to learn,” he adds. “We will learn some things that work in virtual visits, and we will learn some things that absolutely don’t work.” 

That includes addressing three specific goals: Make sure all online content is from a trusted source, be prepared to adopt all-digital transactions, and focus on engagement, both to get patients through the digital door and to keep them there for future care. 

With regard to future care, Martin says “we’re already thinking of the new normal.” That means preparing to transition from Coronavirus triage and care to a platform that can take on elective procedures, chronic care management and specialty care. 

Martin expects the healthcare industry, pushed by consumer demand and the successes of using technology during the pandemic, to pressure state and federal regulators to keep guidelines in place that expand telehealth coverage and reimbursement. But he also expects the industry will see an increase in fraud and abuse, as some look to take advantage of that new normal. 

“There’s going to be some time to adjust,” he says. “Let’s just make sure we don’t back ourselves into a corner (with new legislation) that we can’t get out of.” 

‘We Know It’s a Marathon’ 

At Houston Methodist, the health system has weathered the likes of Hurricanes Allison and Harvey, not to mention the surge of people displaced by Hurricane Katrina. Stephen Spielman, Senior Vice President of the Houston Methodist Physician Organization and President of the Methodist Primary Care Group, says the seven-hospital system has learned a lot from past disasters. 

“We’ve been through this – we know how this feels,” he says. “We know it’s a marathon.” 

Spielman says the health system has been expanding its platform since partnering with American Well some three years ago on its first virtual care service, and now has a broad network of services. 

The Coronavirus pandemic, however, pushed the health system into uncharted territory. 

He says Houston Methodist’s Virtual Urgent Care service worked well in the direct-to-consumer arena – handling the increase from 30-40 visits a day to 250-300 visits – but it didn’t mesh well with the network’s Epic electronic health record, giving providers fits as they tried to conduct telehealth visits with established patients. So the health system created a second telehealth network on the Epic MyChart platform, allowing providers to integrate primary and specialty care visits with each patient’s EMR. 

“This gave us better flexibility, and our physicians loved it,” Spielman says, adding that the shift to a virtual platform took only 10 days. It’s also giving network executives the confidence to push ahead with their third connected health platform: E-visits. 

Along the way, Spielman says he’s learned some interesting lessons. 

While federal authorities loosened the guidelines for video visits through consumer-friendly platforms like Skype and FaceTime, “it’s been a little bit cumbersome to do that operationally,” he says. Those tools might be great for quick, one-off visits demanded by the epidemic, but they don’t integrate will with the health system’s telemedicine infrastructure – and likely won’t be an option when the emergency passes and some of the old rules and regulations come back into play. 

On the other hand, Spielman says he’s had great success with the Press Gainey patient surveys sent out after every telehealth encounter, giving health system executives a good idea of what patients like and don’t like about virtual care. With so many people quarantined at home, more patients have time on their hand to complete those surveys. 

At present, Spielman says Houston Methodist is ramping up its telehealth platforms to not only deal with an expected surge in Coronavirus cases, but to give patients with other needs – treatment for issues not related to the pandemic – the same access to virtual care as those with the virus. The health system is also looking to expand its telemental health offerings to help staff dealing with the stress of the pandemic. 

Looking ahead, he says the health network will look to keep the momentum going after the emergency by expanding its telehealth services for chronic care management, health and wellness and other ancillary services that have been pushed to the side to tackle the virus. 

“What we’re learning here will change healthcare permanently,” he says. “The genie is out of the bottle. Telehealth is our passion now.”

Source: https://mhealthintelligence.com/news/using-telehealth-in-a-pandemic-focus-on-flexibility-scalability

Tags: , , , ,
Posted in All Recent Posts | Comments Off on Using #Telehealth in a #Pandemic #Covid19: Focus on Flexibility, Scalability – SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

« Older Entries
Newer Entries »